The University of Chicago Header Logo

Connection

George Bakris to Hypoglycemic Agents

Back to Details
This is a "connection" page, showing publications George Bakris has written about Hypoglycemic Agents.
George Bakris
Connection Strength
6.875
Hypoglycemic Agents
  1. Chronic Kidney Disease in Type 2 Diabetes: Optimizing Glucose-Lowering Therapy. J Fam Pract. 2019 10; 68(8):S1-S6.
    View in: PubMed
    Score: 0.574
  2. SGLT2 Inhibitors and Mechanisms of Hypertension. Curr Cardiol Rep. 2018 01 19; 20(1):1.
    View in: PubMed
    Score: 0.510
  3. Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? Yes, They Should Be Relaxed! What's the Fuss? Diabetes Care. 2016 Jul; 39(7):1287-91.
    View in: PubMed
    Score: 0.458
  4. Hypertension: SGLT2 inhibitors: not just another glucose-lowering agent. Nat Rev Nephrol. 2016 Mar; 12(3):128-9.
    View in: PubMed
    Score: 0.442
  5. Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes Care. 2015 Mar; 38(3):429-30.
    View in: PubMed
    Score: 0.418
  6. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014; 40(1):64-74.
    View in: PubMed
    Score: 0.400
  7. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014 May; 8(5):330-9.
    View in: PubMed
    Score: 0.388
  8. Noninsulin glucose-lowering agents for the treatment of patients on dialysis. Nat Rev Nephrol. 2013 Mar; 9(3):147-53.
    View in: PubMed
    Score: 0.361
  9. Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab. 2010 Dec; 12(12):1079-83.
    View in: PubMed
    Score: 0.311
  10. Effects of thiazolidinediones beyond glycaemic control. Curr Pharm Des. 2009; 15(5):529-36.
    View in: PubMed
    Score: 0.272
  11. The antinatriuretic effect of insulin: an unappreciated mechanism for hypertension associated with insulin resistance? Am J Nephrol. 2007; 27(1):44-54.
    View in: PubMed
    Score: 0.238
  12. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006 Oct; 24(10):2047-55.
    View in: PubMed
    Score: 0.233
  13. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 2006 Oct; 70(7):1223-33.
    View in: PubMed
    Score: 0.230
  14. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens. 2003 Jan; 17(1):7-12.
    View in: PubMed
    Score: 0.180
  15. Use of SGLT-2 Inhibitors to Treat Chronic Kidney Disease in Primary Care. J Fam Pract. 2022 07; 71(6 Suppl):S88-S93.
    View in: PubMed
    Score: 0.174
  16. Oral antidiabetic agents safe with renal disease? Postgrad Med. 2000 Jun; 107(7):66.
    View in: PubMed
    Score: 0.150
  17. High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. Diabetes Obes Metab. 2018 03; 20(3):654-659.
    View in: PubMed
    Score: 0.126
  18. Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care. 2016 Dec; 39(12):2304-2310.
    View in: PubMed
    Score: 0.117
  19. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. Diabetes Care. 2016 Jul; 39(7):1267-73.
    View in: PubMed
    Score: 0.114
  20. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. Eur Heart J Cardiovasc Pharmacother. 2016 07; 2(3):200-5.
    View in: PubMed
    Score: 0.113
  21. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015 May 23; 385(9982):2067-76.
    View in: PubMed
    Score: 0.105
  22. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014 Oct; 16(10):1016-27.
    View in: PubMed
    Score: 0.100
  23. Metformin nephrotoxicity insights: will they change clinical management? J Diabetes. 2014 Mar; 6(2):111-2.
    View in: PubMed
    Score: 0.096
  24. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 03; 369(14):1327-35.
    View in: PubMed
    Score: 0.094
  25. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013 May; 15(5):463-73.
    View in: PubMed
    Score: 0.091
  26. Diabetes and chronic kidney disease: tragedy and challenge. Blood Purif. 2004; 22(1):130-5.
    View in: PubMed
    Score: 0.048
  27. Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial. Lancet Diabetes Endocrinol. 2023 Dec; 11(12):892-894.
    View in: PubMed
    Score: 0.048
  28. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023 08 31; 38(9):2041-2051.
    View in: PubMed
    Score: 0.047
  29. Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations. J Am Coll Cardiol. 2023 06 27; 81(25):2377-2387.
    View in: PubMed
    Score: 0.046
  30. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2022 02; 36(2):108101.
    View in: PubMed
    Score: 0.042
  31. Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial. Clin Res Cardiol. 2021 Jul; 110(7):1006-1019.
    View in: PubMed
    Score: 0.038
  32. Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus. Am Heart J. 2020 11; 229:40-51.
    View in: PubMed
    Score: 0.038
  33. Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial. Circulation. 2020 02 04; 141(5):407-410.
    View in: PubMed
    Score: 0.036
  34. Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. J Am Heart Assoc. 2018 10 16; 7(20):e009114.
    View in: PubMed
    Score: 0.034
  35. Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). Circulation. 2017 May 16; 135(20):1911-1921.
    View in: PubMed
    Score: 0.030
  36. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial. Diabetes Obes Metab. 2017 05; 19(5):664-671.
    View in: PubMed
    Score: 0.030
  37. Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes. 2017 02; 66(2):241-255.
    View in: PubMed
    Score: 0.030
  38. Regression to the Mean in SYMPLICITY HTN-3: Implications for Design and Reporting of Future Trials. J Am Coll Cardiol. 2016 11 01; 68(18):2016-2025.
    View in: PubMed
    Score: 0.029
  39. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension. 2016 09; 68(3):606-13.
    View in: PubMed
    Score: 0.029
  40. Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. Am Heart J. 2016 May; 175:18-27.
    View in: PubMed
    Score: 0.028
  41. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis. 2014 Oct; 64(4):510-33.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.